Esperion Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Esperion Therapeutics

23/02/2024 16:50

* Esperion Therapeutics Inc  ESPR.OQ   ESPR.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
27 for the period ending December 31 2023
    * The Vero Beach Florida-based  company is expected to
report a
52.5% increase in revenue to $28.698 million from $18.82 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Esperion Therapeutics
Inc is
for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Esperion
Therapeutics Inc is $8.00​, above​ its last closing price
of $2.63. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.43       -0.43      -0.37     Beat    14.4
 Jun. 30 2023  -0.62       -0.61      -0.46     Beat    24.8
 Mar. 31 2023  -0.64       -0.65      -0.79     Missed  -21.1​
 Dec. 31 2022  -0.82       -0.84      -0.76     Beat    9.6
 ​​Sep.        -0.92       -0.92      -0.81     Beat    12.4
 30 2022                                                
 Jun. 30 2022  -0.92       -0.93      -1.05     Missed  -13.4​
 Mar. 31 2022  -0.99       -1.04      -0.93     Beat    10.9
 Dec. 31 2021  -2.22       -2.27      -1.77     Beat    22
 This summary was machine generated February 23 at 16:50 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)